Medigene AG to be included in TecDAX Index
(Thomson Reuters ONE) -
Medigene AG /
Medigene AG to be included in TecDAX Index
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/München, 6 December 2016. Medigene AG (Frankfurt, Prime Standard,
MDG1) has been selected for inclusion on the TecDAX, an index of the Deutsche
Börse (German Stock Exchange) that includes Germany's most important mid-cap
technology companies. The TecDAX follows the Blue Chip DAX index and comprises
30 companies admitted to the stock market "Prime Standard" segment. In addition
to compliance with comprehensive international transparency requirements, the
admission criteria include an above-average market capitalization (share price
multiplied by the number of company shares), and a high trading volume (number
of shares traded daily). According to the decision made by Deutsche Börse on 5
December 2016, Medigene has fulfilled the admission criteria for the TecDAX and
will be included there as of 19 December 2016.
Prof Dolores Schendel, CEO of Medigene AG, comments: "TecDAX membership
signifies Medigene's position among the leading German technology securities.
This admission reflects the dynamic development Medigene has made following its
strategic refocussing on the development of highly innovative cancer
immunotherapies. The TecDAX listing increases Medigene's visibility in the
capital markets and facilitates our collaboration with domestic and
international investors."
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. The Company develops
highly innovative, complementary treatment platforms to target various forms and
stages of cancer with drug candidates in clinical and pre-clinical development.
Medigene concentrates on the development of personalized T-cell-based
immunotherapies.
More information is available at www.medigene.de
This press release contains certain statements relating to the future. They
represent the opinion of Medigene as of the date of this release. The actual
results achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these forward-
looking statements Medigene(R) is a registered trademark of Medigene AG. This
trademark may be held or licensed for specific countries.
Contact Medigene
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
Should you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor(at)medigene.com). We will then delete your address
from our distribution list.
press release TecDAX:
http://hugin.info/132073/R/2062116/773543.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2016 - 11:21 Uhr
Sprache: Deutsch
News-ID 511029
Anzahl Zeichen: 3576
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene AG to be included in TecDAX Index"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
